Journal
JOURNAL OF INFECTIOUS DISEASES
Volume 185, Issue 5, Pages 686-690Publisher
UNIV CHICAGO PRESS
DOI: 10.1086/339003
Keywords
-
Categories
Funding
- NIAID NIH HHS [AI-45252] Funding Source: Medline
- NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI045252] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Development of a vaccine for prevention of congenital cytomegalovirus (CMV) disease is a priority. This study evaluated a prime-boost strategy by comparing the safety and immunogenicity of 3 doses of subunit CMV glycoprotein B (gB) vaccine plus MF59 (a squalene-in-water emulsion), 2 doses of a canarypox recombinant vaccine expressing CMVgB (ALVAC-CMVgB) followed by 2 doses of the subunit gB vaccine, 3 doses of both vaccines administered concomitantly, and placebo in 105 healthy, CMV-seronegative adults. Systemic adverse events were rare, but local reactions were common in all groups. After the first subunit vaccination, neutralizing antibody titers in the prime-boost group were comparable to those in subjects receiving 2 subunit vaccinations, indicating a priming effect of ALVAC-CMVgB. However, after the final dose, antibody and cell-mediated immune responses were not significantly different among the groups. All 3 vaccine regimens induced high-titer antibody and lymphoproliferative responses, but no benefit for priming or simultaneous vaccination was detected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available